Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NASDAQ:BCAB NASDAQ:EGRX NASDAQ:GNPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.48+2.3%$5.05$1.00▼$7.00$39.73M0.413,416 shs10,501 shsBCABBioAtla$0.62-10.0%$0.45$0.24▼$2.53$36.52M0.921.06 million shs829,613 shsEGRXEagle Pharmaceuticals$3.37+10.1%$3.34$1.50▼$3.87$23.38M0.836,074 shs1,564 shsGNPXGENPREX$0.23-4.9%$0.23$0.14▼$3.97$9.98M-0.6523.94 million shs2.51 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics+2.28%-8.20%-10.93%+5.91%+273.33%BCABBioAtla-10.00%-19.74%+65.71%+54.93%-62.54%EGRXEagle Pharmaceuticals+10.13%+4.98%+5.64%+17.22%-21.26%GNPXGENPREX-4.87%-20.26%+42.79%-11.86%-36.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.48+2.3%$5.05$1.00▼$7.00$39.73M0.413,416 shs10,501 shsBCABBioAtla$0.62-10.0%$0.45$0.24▼$2.53$36.52M0.921.06 million shs829,613 shsEGRXEagle Pharmaceuticals$3.37+10.1%$3.34$1.50▼$3.87$23.38M0.836,074 shs1,564 shsGNPXGENPREX$0.23-4.9%$0.23$0.14▼$3.97$9.98M-0.6523.94 million shs2.51 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics+2.28%-8.20%-10.93%+5.91%+273.33%BCABBioAtla-10.00%-19.74%+65.71%+54.93%-62.54%EGRXEagle Pharmaceuticals+10.13%+4.98%+5.64%+17.22%-21.26%GNPXGENPREX-4.87%-20.26%+42.79%-11.86%-36.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00167.86% UpsideBCABBioAtla 2.00HoldN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/AGNPXGENPREX 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GNPX, BCAB, EGRX, and ATHE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025BCABBioAtlaJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform8/13/2025BCABBioAtlaCitizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/ABCABBioAtla$11M3.32N/AN/A$0.25 per share2.49EGRXEagle Pharmaceuticals$257.55M0.17$8.43 per share0.40N/A∞GNPXGENPREXN/AN/AN/AN/A$0.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$7.87MN/A0.00∞N/AN/AN/AN/AN/ABCABBioAtla-$69.78M-$1.10N/AN/AN/AN/A-1,177.18%-137.51%11/6/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AGNPXGENPREX-$21.11MN/A0.00N/AN/AN/A-809.27%-386.95%11/12/2025 (Estimated)Latest GNPX, BCAB, EGRX, and ATHE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GNPXGENPREX-$0.71-$0.17+$0.54-$0.17N/AN/A8/7/2025Q2 2025BCABBioAtla-$0.29-$0.31-$0.02-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/ABCABBioAtlaN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AGNPXGENPREXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A12.9812.98BCABBioAtlaN/A1.241.24EGRXEagle PharmaceuticalsN/AN/AN/AGNPXGENPREXN/A0.840.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%BCABBioAtla77.23%EGRXEagle Pharmaceuticals85.36%GNPXGENPREX14.05%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%BCABBioAtla11.22%EGRXEagle Pharmaceuticals28.90%GNPXGENPREX0.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableBCABBioAtla6058.72 million52.13 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataGNPXGENPREX2042.90 million42.72 millionNo DataGNPX, BCAB, EGRX, and ATHE HeadlinesRecent News About These CompaniesGenprex (NASDAQ:GNPX) Stock Price Down 5.7% - Should You Sell?September 16, 2025 | americanbankingnews.comGenprex files to sell 25M shares of common stock for holdersSeptember 12, 2025 | msn.comGenprex Stockholders Approve Key Proposals at Annual MeetingSeptember 3, 2025 | theglobeandmail.comGenprex to Present and Participate at Upcoming September Investor and Industry ConferencesSeptember 2, 2025 | prnewswire.comGenprex receives notice of allowance for multiple patents for ReqorsaAugust 18, 2025 | msn.comGenprex Secures Patent Allowances for Gene TherapyAugust 18, 2025 | tipranks.comGenprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat CancersAugust 18, 2025 | prnewswire.comGenprex Issues Stockholder Letter and Provides 2025 Corporate UpdateAugust 4, 2025 | prnewswire.comGenprex, Inc. (GNPX) Latest Stock News & Headlines - Yahoo FinanceJune 27, 2025 | finance.yahoo.comGenprex reports positive results from diabetes gene therapy studyJune 25, 2025 | investing.comGenprex Announces Positive Preclinical Results for GPX-002June 24, 2025 | tipranks.comGenprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific SessionsJune 24, 2025 | prnewswire.comGenprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific SessionsJune 23, 2025 | prnewswire.comGenprex to Participate at BIO 2025 International ConventionJune 3, 2025 | prnewswire.comGenprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual MeetingMay 29, 2025 | prnewswire.comGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual MeetingMay 28, 2025 | prnewswire.comGenprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetesMay 9, 2025 | bioworld.comBGenprex inks sponsored research agreement with the University of Pittsburgh to study diabetes gene therapy in Type 1 and Type 2 diabetesMay 8, 2025 | pharmabiz.comPGenprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 DiabetesMay 7, 2025 | prnewswire.comGenprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of GlioblastomaMay 6, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNPX, BCAB, EGRX, and ATHE Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$4.48 +0.10 (+2.28%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$4.44 -0.04 (-0.89%) As of 09/19/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.BioAtla NASDAQ:BCAB$0.62 -0.07 (-10.00%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.62 0.00 (-0.47%) As of 09/19/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Eagle Pharmaceuticals NASDAQ:EGRX$3.37 +0.31 (+10.13%) As of 09/19/2025 02:58 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.GENPREX NASDAQ:GNPX$0.23 -0.01 (-4.87%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.23 0.00 (-1.98%) As of 09/19/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
